Delivery of progestins via the subdermal versus the intrauterine route: comparison of the pharmacology and clinical outcomes.
| Title: | Delivery of progestins via the subdermal versus the intrauterine route: comparison of the pharmacology and clinical outcomes. |
|---|---|
| Authors: | Goldstuck ND; a Department of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences , University of Stellenbosch , Bellville , Western Cape , South Africa.; Le HP; b Department of Physical Sciences , MacEwan University , Edmonton , Alberta , Canada. |
| Source: | Expert opinion on drug delivery [Expert Opin Drug Deliv] 2018 Jul; Vol. 15 (7), pp. 717-727. Date of Electronic Publication: 2018 Jul 18. |
| Publication Type: | Comparative Study; Journal Article; Review |
| Language: | English |
| Journal Info: | Publisher: Informa Healthcare Country of Publication: England NLM ID: 101228421 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-7593 (Electronic) Linking ISSN: 17425247 NLM ISO Abbreviation: Expert Opin Drug Deliv Subsets: MEDLINE |
| Imprint Name(s): | Publication: London : Informa Healthcare; Original Publication: London : Ashley Publications, Ltd. |
| MeSH Terms: | Contraceptive Agents, Female/*administration & dosage ; Progestins/*administration & dosage; Desogestrel/administration & dosage ; Levonorgestrel/administration & dosage ; Female ; Humans ; Pregnancy |
| Abstract: | Introduction: Subdermal and intrauterine progestin releasing systems are two types of long-acting reversible contraceptive systems (LARC). Their use has transformed current contraceptive practice management. There is not much objective evidence to help decide which method is preferable and in which particular circumstance using objective criteria.; Areas Covered: MEDLINE, POPLINE, PubMed, and clinicaltrials.gov were searched using the terms "implant" vs "IUS" and then adding the terms "levonorgestrel" and "etonogestrel" to the implant arm and "levonorgestrel" to the IUS arm. This was done using commercial names as well for the terms "pharmacodynamics" and "pharmacokinetics" as well as for the term "therapeutic." Preference was given to comparative studies of the highest degree.; Expert Opinion: Under normal circumstances, user satisfaction appeared marginally greater for intrauterine rather than subdermal progestin provision. However, after uterine events such as pregnancy or surgical evacuation of the uterus, implants performed better. Intrauterine progestin is preferable for therapeutic purposes. |
| Contributed Indexing: | Keywords: LARC; Progestin; etonogestrel; hormone-releasing IUS; levonorgestrel; subdermal implant; therapeutic |
| Substance Nomenclature: | 0 (Contraceptive Agents, Female); 0 (Progestins); 304GTH6RNH (etonogestrel); 5W7SIA7YZW (Levonorgestrel); 81K9V7M3A3 (Desogestrel) |
| Entry Date(s): | Date Created: 20180707 Date Completed: 20190128 Latest Revision: 20190723 |
| Update Code: | 20260130 |
| DOI: | 10.1080/17425247.2018.1498080 |
| PMID: | 29979891 |
| Database: | MEDLINE |
Comparative Study; Journal Article; Review